Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026
Globe Newswire•12/10/2026•08:00 ET
0
Key Highlights
- ➤VOQUEZNA projected healthcare savings versus PPIs at estimated net price
- ➤VOQUEZNA projected cost-effective versus PPIs at WAC price
- ➤WAC ICERs were $28,402 and $18,878 per QALY
- ➤VOQUEZNA treatment effects persisted across BMI subgroups in Non-Erosive GERD
- ➤38 independent vonoprazan abstracts presented at ACG 2026
Expert Statements
Steve Basta, President and Chief Executive Officer of Phathom Pharmaceuticals
“These new findings highlight the potential cost-effectiveness of VOQUEZNA for patients with Erosive GERD and provide new insights into how clinical outcomes may translate into healthcare savings over time”
Steve Basta, President and Chief Executive Officer of Phathom Pharmaceuticals
“We’re also encouraged by the continued growth in independent research evaluating vonoprazan across a wide range of GI conditions, which speaks to the broader scientific and clinical interest in this therapeutic class of acid suppression.”
* New analysis projects VOQUEZNA® (vonoprazan) to provide meaningful economic value and be cost-effective vs. proton pump inhibitors (PPIs) for adults with Erosive GERD, with potential cost savings at net price based on clinical healing and maintenance-of-healing data and fewer anticipated downstream complications
* Additional Phathom-sponsored data highlight VOQUEZNA treatment effect across BMI subgroups in Non-Erosive GERD and real-world patient characteristics
Get started
Create a free account to read the full story.